Related Experiment Video
Updated: May 11, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Expression of Lewis X is associated with poor prognosis in triple-negative breast cancer
Young Wha Koh1, Hee Jin Lee, Jin-Hee Ahn
1Dept of Pathology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea.
Abstract:
The Lewis X (Le(X)) antigen is a prognostic marker in certain solid tumors and has been proposed as a therapeutic target. Immunohistochemical analyses were performed to retrospectively examine the prognostic impact of Le(X) expression in 158 patients with triple-negative breast cancer (TNBC). Twenty-three (14.5%) patients were Le(X)-positive. Multivariate analysis showed that Le(X) positivity was an independent poor prognostic factor for recurrence-free survival (RFS) and overall survival (OS) (P = .037 and P = .024, respectively). Le(X) expression was a prognostic factor for survival in stage I/II and stage III TNBCs. Subgroup analysis according to age showed that Le(X) positivity was only associated with poor RFS and OS in younger patients with TNBC (age < 50 years) (P < .001 and P < .001, respectively). Our results suggest that Le(X) expression is an independent prognostic factor for RFS and OS in younger patients with TNBC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
lncRNA - Long Non-coding RNAs